Synthetic Biologics Stock Price - SYN

Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
$52.04
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
$67.09
Level 1 Starter
Monthly Subscription
for only
$15.87
VAT not included
Company Name Stock Ticker Symbol Market Type
Synthetic Biologics Inc SYN AMEX Common Stock
  Price Change Change Percent Stock Price High Price Low Price Open Price Close Price Last Traded
  0.0011 0.28% 0.399 0.4095 0.3902 0.40 0.3979 19:59:43
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
162 47,209 $ 0.3970751 $ 18,746 78,670 0.365 - 0.9333
Last Trade Time Type Quantity Stock Price Currency
19:59:43 100 $ 0.399 USD

Synthetic Biologics Financials

Market Cap Shares in Issue Profit/Loss Earnings Per Share (EPS) PE Ratio Float
$ 6.71M 16.81M $ -13.37M -4.07 - 11.24M
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
183.96k $ - 0.00% 1.00 33.10%

more financials information »

Synthetic Biologics News

Loading Messages....

Latest SYN Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical SYN Price Data

Period † Open High Low VWAP Avg. Daily Vol [m] Change %
1 Week0.4010.440.37810.391939k-0.002-0.50%
1 Month0.470.540.37810.444068k-0.071-15.11%
3 Months0.5330.560.3650.449386k-0.134-25.14%
6 Months0.580.650.3650.510994k-0.181-31.21%
1 Year0.87230.93330.3650.6827217k-0.4733-54.26%
3 Years56.3557.050.36517.9855766k-55.951-99.29%
5 Years55.3151.20.36547.7697861k-54.901-99.28%

Synthetic Biologics Description

Synthetic Biologics is a late-stage biotechnology company focused on developing gut microbiome therapeutics. Its portfolio includes SYN-010, which is intended to treat the underlying causes of irritable bowel syndrome with constipation; and SYN-004 (ribaxamase), which aims to defend the gut microbiome from the effects of regularly used intravenous drugs for the prevention of C. difficile infection, antibiotic-associated diarrhea, and the emergence of antibiotic-resistant organisms. The company is also developing monoclonal antibody therapies for the treatment of pertussis and novel discovery-stage biotherapeutics for the treatment of phenylketonuria.


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.